Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 6Phase 1/2 3Phase 2/3 1

Status

Completed 8Terminated 3Active not recruiting 2Unknown 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 2Head & Neck 1

Conditions

Melanoma 2Thyroid Neoplasms 1Carcinoma, Medullary 1

Interventions

pembrolizumab 75Carboplatin 61Cyclophosphamide 58Nivolumab 50Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 35Rituximab 32Capecitabine 31Docetaxel 29Bevacizumab 29fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Fluorouracil 22Azacitidine 22Temozolomide 21Ipilimumab 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × Dacarbazine × Clear all
NCT00615160 2021-10-06

PTK/ZK in Disseminated Malignant Melanoma

University Hospital Schleswig-Holstein

Phase 1/2 Terminated
9 enrolled
Dermatologic

Melanoma

NCT00354523 2014-12-17

Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
21 enrolled
Head & Neck

Thyroid Neoplasms, Carcinoma, Medullary

NCT00496223 2011-02-23

A Phase I/II Study of Sunitinib and Dacarbazine

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Terminated
11 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡